CIK细胞治疗晚期恶性肿瘤的临床研究  

Clinical study of cytokine-induced killer cell transfusion in the treatment of advanced malignant tumor

作　　者：任庆[1] 熊锐华[1] 田秀荣[1] 罗克品[1] 周欣[1] 

机构地区：[1]中国人民解放军第181医院肿瘤治疗中心,广西桂林541002

出　　处：《湖南中医药大学学报》2012年第10期55-57,共3页Journal of Hunan University of Chinese Medicine

摘　　要：目的探讨细胞因子诱导的杀伤细胞(CIK)治疗晚期恶性肿瘤的临床疗效。方法收治42例无手术、放、化疗指征的晚期恶性肿瘤患者,将CIK细胞输注给患者,观察其近、远期疗效、不良反应,比较患者治疗前后外周血的T淋巴细胞亚群(CD3+、CD4+、CD8+、CD16+CD56+)分布、生活质量的变化。结果 42例患者均可评价疗效及不良反应。经CIK细胞治疗后客观缓解率为16.7%,CD3+、CD4+、CD8+、CD16+CD56+均有明显的升高,生活质量评分显著改善,中位无进展生存期(progression free survival,PFS)为8.1个月,中位生存期(overall survival,OS)为12.8个月,仅少数患者输注过程中出现发热,未见其他不良反应。结论应用CIK细胞输注治疗晚期恶性肿瘤可提高患者的细胞免疫功能,提高生活质量,延长生存期,且无明显不良反应,具有一定的临床使用价值。Objective The purpose of this study was to observe clinical efficacy of cytokine-induced killer cell（CIK） in the treatment of advanced malignant tumor.Methods A total of 42 patients with malignant tumor that can not be surgeryed or radiotherapyed and chemotherapy at all received CIK to therapy.Such as T lymph cell subpopulation（CD3＋、CD4＋、CD8＋、CD16＋CD56＋,quality of life,short-term response and long-term rate was observed after therapy.Results A total of 42 patients can be evaluated the efficiency and toxicity.The response rates was 16.7%.CD3＋、CD4＋、CD8＋、CD16＋CD56＋ was obviously raised in all patients,Symptom and quality of life was received significant improve.,PFS was 8.1 months,OS was 12.8months.A few patients geted ferves in transfusion,The adverse reaction of patients was mild.Conclusion The cytokine-induced killer cell（CIK） that can improve clinical symptom and quality of life,prolong overall survival,furthermore no toxicities was clinical

关 键 词：CIK细胞 恶性肿瘤 过继免疫治疗 

分 类 号：R730.51[医药卫生—肿瘤]